EGLN3 and prostate carcinoma: EGLN3 was also documented as a proapoptotic factor in considerable work, including neural crest derivatives, osteosarcoma cells, prostatic carcinoma cells, lung carcinoma cells, and colorectal carcinoma cells [20, 25–30].